secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095450
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data
-------------------------------------------------------------------------------

- Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.
- Cash, equivalents and short-term investments $19.1M as of June 30, 2024; runway into H2 2025.
- Phase 2b CARPO trial for Auxora in acute pancreatitis met primary objective with statistically significant dose response.
- First patient dosed in Phase 2 KOURAGE trial for severe AKI; topline data expected in 2025.
- Company added to Russell Microcap Index effective July 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/0000950170-24-095450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/ck0001534133-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer